StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson DARZALEX (daratumumab) by Quarter

DARZALEX (daratumumab) — Worldwide operational (constant-currency) growth YoY (%) (%)

QuarterlyAnnual

Johnson & Johnson DARZALEX (daratumumab): 15.6% in Q3 2026, down 4.3 pts from a year earlier. That is the lowest of the 36 quarters on record here.

Latest, Q3 2026
15.6%
Period ended Sep 30, 2026
Change on a year earlier
-4.3 pts
19.9% in Q3 2025
History
36 quarters
Since Q4 2017
Sources
36
Documents cited below

Where the Q3 2026 figure comes from

“|| WW | 4,239 | 3,672 | 15.4 | 15.6 | (0.2)”

Source: Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗

Reported in Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDARZALEX (daratumumab) — Worldwide operational (constant-currency) growth YoY (%) (%)Year on yearSource
Q3 2026Sep 30, 202615.6%-4.3 ptsForm 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Q2 2026Jun 28, 202617.6%-3.9 ptsForm 8-K (a2026q2exhibit991.htm, filed 2026-07-15) ↗
Q1 2026Mar 29, 202617.8%-4.7 ptsForm 8-K (a2026q1exhibit991.htm, filed 2026-04-14) ↗
Q4 2025Dec 28, 202524.1%+0.6 ptsForm 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Q3 2025Sep 28, 202519.9%-3.0 ptsForm 8-K (a2025q3exhibit991.htm, filed 2025-10-14) ↗
Q2 2025Jun 29, 202521.5%+0.2 ptsForm 8-K (a2025q2exhibit991.htm, filed 2025-07-16) ↗
Q1 2025Mar 30, 202522.5%+1.5 ptsForm 8-K (a2025q1exhibit991.htm, filed 2025-04-15) ↗
Q4 2024Dec 29, 202423.5%+1.3 ptsForm 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗
Q3 2024Sep 29, 202422.9%+2.2 ptsForm 8-K (a2024q3exhibit991.htm, filed 2024-10-15) ↗
Q2 2024Jun 30, 202421.3%-2.1 ptsForm 8-K (a2024q2exhibit991.htm, filed 2024-07-17) ↗
Q1 2024Mar 31, 202421.0%-4.7 ptsForm 8-K (a2024q1exhibit991.htm, filed 2024-04-16) ↗
Q4 2023Dec 31, 202322.2%-11.7 ptsForm 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗
Q3 2023Oct 1, 202320.7%-18.0 ptsForm 8-K (a2023q3exhibit991.htm, filed 2023-10-17) ↗
Q2 2023Jul 2, 202323.4%-22.7 ptsForm 8-K (a2023q2exhibit991.htm, filed 2023-07-20) ↗
Q1 2023Apr 2, 202325.7%-14.6 ptsForm 8-K (a2023q1exhibit991.htm, filed 2023-04-18) ↗
Q4 2022Jan 1, 202333.9%+0.5 ptsForm 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗

Breakdown

What makes up DARZALEX (daratumumab)

Cite this data

StockData. (2026). Johnson & Johnson DARZALEX (daratumumab) (%), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-darzalex-ops-yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.